Mind Medicine
Stock
Stock
ISIN: CA60255C8850
Ticker: MNMD
CA60255C8850
MNMD
Price
Price
CHART BY
Frequently asked questions
What is Mind Medicine's market capitalization?
The market capitalization of Mind Medicine is $201.65M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Mind Medicine?
Mind Medicine's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.085. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Mind Medicine's stock?
Currently, 9 analysts cover Mind Medicine's stock, with a consensus target price of $25.89. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Mind Medicine?
Mind Medicine's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$92.34M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Mind Medicine?
Mind Medicine has a free cash flow of -$73.36M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Mind Medicine have, and what sector and industry does it belong to?
Mind Medicine employs approximately 57 people. It operates in the Health Care sector, specifically within the Pharmaceuticals: Major industry.
What is the free float of Mind Medicine's shares?
The free float of Mind Medicine is 27.25M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $201.65M
- EPS (TTM)
- -$2.085
- Free Float
- 27.25M
- EBITDA (TTM)
- -$92.34M
- Free Cashflow (TTM)
- -$73.36M
Pricing
- 1D span
- $7.131$7.37
- 52W span
- $3.50$12.15
Analyst Ratings
The price target is $25.89 and the stock is covered by 9 analysts.
Buy
9
Hold
0
Sell
0
Information
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.
- Employees
- 57
- Industries
- Pharmaceuticals: Major
- Sector
- Health Care
Identifier
- ISIN
- CA60255C8850
- Primary Ticker
- MNMD